Denmark combines a population of just 5.9 million with more than 4,000 trials listed on ClinicalTrials.gov and one of Europe’s most sophisticated health data infrastructures.
Its clinical research ecosystem is concentrated around Copenhagen, Aarhus, Odense and Aalborg, with major institutions including Rigshospitalet, Aarhus University Hospital and Steno Diabetes Center Copenhagen providing strong Phase I to Phase IV capabilities.
Denmark’s defining advantage for sponsors is connectivity.
National health registers linked through Denmark’s individual identification system can support longitudinal research and long term outcome follow up under appropriate governance and approvals. The country’s cancer registry dates back to 1943, while additional national registries cover hospital activity, prescriptions and psychiatric care.
Denmark also has exceptional therapeutic depth in metabolic research. Novo Nordisk, the Novo Nordisk Foundation and Steno Diabetes Center have helped create a highly experienced investigator ecosystem across diabetes, obesity and broader cardiometabolic development.
Oncology, neuroscience, psychiatry, dermatology, cardiovascular research, rare disease and real world evidence provide additional areas of strength.
For sponsors, Denmark can therefore offer something more specific than general Nordic research quality: specialist investigators, centralized academic expertise, longitudinal health data and strong pharma infrastructure within a geographically compact market.